Methylgene, Inc.

Other

Forum Pharmaceuticals, Inc.

Tranzyme Pharma Inc.

Boehringer Ingelheim Ltd./ Boehringer Ingelheim Ltee

Robert Deziel

Alain Ajamian

Silvana Leit

Yves Andre Chantigny

Pierre Tessier

David Smil

Arkadii Vaisburg

Stephane Raeppel

Franck Raeppel

Patrick Beaulieu

John Mancuso

Richard Chesworth

Celia Dominguez

Gideon Shapiro

Oscar Miguel Moradei

Eric Marsault

Mark L Peterson

Stephen Claridge

Lijie Zhan

Jeffrey M Besterman

Michael Mannion

Ljubomir Isakovic

Oscar Mario Saavedra

Sylvie Frechette

Sylvie Beaubien

Isabelle Paquin

Simon Roy

Tammy Mallais

Nancy Z Zhou

Nafsika Georgopapadakou

Roger Machaalani

Jean Bedard

Nadia Campeol

Wenqi Hu

Oscar Moradei

Hamid Hoveyda

Stephen William Claridge

Neil Moss

Kamel Benakli

Graeme Fraser

Tammy C Mallais

The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.

Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.

Inhibitors of histone deacetylase

The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.

Histone deacetylase inhibitors for enhancing activity of antifungal agents

This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification. 

The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of VEGF receptor and HGF receptor signaling

Growing community of inventors

Mount-Royal, Canada

Robert Deziel